Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 11 de 11
Filtrar
1.
Urol Pract ; 11(3): 538-546, 2024 May.
Artigo em Inglês | MEDLINE | ID: mdl-38640417

RESUMO

INTRODUCTION: The use of active surveillance (AS) for prostate cancer is increasing, and racial disparities have been identified in its implementation. We investigated differences by race and ethnicity in the utilization and intensity of AS by race and ethnicity among older men with low- and favorable intermediate-risk prostate cancer, with particular focus on the integration of multiparametric MRI (mpMRI) into AS protocols. METHODS: Using the Surveillance, Epidemiology, and End Results and Medicare fee-for-service linked database, we identified a cohort of men diagnosed between 2010 and 2017 with low- or favorable intermediate-risk prostate cancer. The odds of receiving AS were compared by patient race and ethnicity using multivariable logistic regression models, while the rates of usage of PSA tests, biopsy, and mpMRI within 2 years of diagnosis among men on AS were assessed using multivariable Poisson regression models. RESULTS: Our cohort included 33,542 men. The proportion of men with low-risk disease who underwent AS increased from 29.5% in 2010 to 51.7% in 2017, while the proportion among men with favorable intermediate disease grew from 11.4% to 17.2%. Hispanic (odds ratio [OR] = 0.68, 95% CI 0.58-0.79) and non-Hispanic Black men (OR = 0.78, 95% CI 0.68-0.89) were less likely to receive AS than non-Hispanic White men for low-risk disease, while non-Hispanic Black men were more likely to receive AS for favorable intermediate disease (OR = 1.21, 95% CI 1.04-1.39). Non-Hispanic Black men receiving AS underwent prostate MRI at a lower rate compared to non-Hispanic White men, regardless of whether they had low-risk (incidence rate ratio = 0.77, 95% CI 0.61-0.97) or favorable intermediate-risk (incidence rate ratio = 0.61, 95% CI 0.44-0.83) disease, respectively. CONCLUSIONS: The overall adoption of AS for low-risk prostate cancer increased among Medicare fee-for-service beneficiaries. However, a significant disparity exists for non-Hispanic Black men, as they exhibit lower rates of AS utilization. Moreover, non-Hispanic Black men are less likely to have access to novel technologies, such as mpMRI, as part of their AS protocols.


Assuntos
Neoplasias da Próstata , Conduta Expectante , Masculino , Humanos , Idoso , Estados Unidos/epidemiologia , Negro ou Afro-Americano , Medicare , Neoplasias da Próstata/diagnóstico por imagem , Brancos
3.
Curr Urol Rep ; 24(11): 527-532, 2023 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-37768551

RESUMO

PURPOSE OF REVIEW: Stress urinary incontinence after prostatectomy is a common and debilitating side effect. Immediate post-prostatectomy management emphasizes pelvic floor muscle exercises. Per American Urologic Association guidelines, if incontinence persists for more than 12 months postoperatively, surgical interventions are the mainstay of treatment. Treatment decisions depend on a multitude of factors. The goal of this paper is to review recent literature updates regarding the diagnosis of male SUI to better guide surgical treatment decision-making. RECENT FINDINGS: Patient history is a critical component in guiding surgical decision making with severity and bother being primary factors driving treatment decisions. Recent studies indicate that a history of pelvic radiation continues to impact the overall duration and complication rate associated with artificial urinary sphincters (AUS). Cystoscopy should be done on every patient preparing to undergo surgical SUI treatment. Urodynamics and standing cough stress tests are additional diagnostic testing options; these tests may augment the diagnosis of SUI and better delineate which patients may benefit from a male sling versus AUS. Treatment of SUI after prostatectomy can improve health-related quality of life. A patient history focused on severity and degree of bother in addition to the use of ancillary office testing can help guide surgical treatment decisions to optimize patient continence goals.


Assuntos
Slings Suburetrais , Incontinência Urinária por Estresse , Incontinência Urinária , Esfíncter Urinário Artificial , Humanos , Masculino , Qualidade de Vida , Resultado do Tratamento , Prostatectomia/efeitos adversos , Incontinência Urinária/diagnóstico , Incontinência Urinária/etiologia , Incontinência Urinária/cirurgia , Incontinência Urinária por Estresse/etiologia , Incontinência Urinária por Estresse/cirurgia , Esfíncter Urinário Artificial/efeitos adversos , Tomada de Decisão Clínica , Slings Suburetrais/efeitos adversos
4.
JNCI Cancer Spectr ; 7(2)2023 03 01.
Artigo em Inglês | MEDLINE | ID: mdl-36840651

RESUMO

Overdiagnosis and overtreatment of low-grade prostate cancer (PCa) reflect poor quality of care and prompted changes to guidelines over the past decade. We used the National Cancer Database to characterize Gleason Grade Group (GG)1 PCa diagnosis trends and assess facility-level treatment variability. Between 2010 and 2019, GG1 PCa incidence had a clinically and statistically significant decline, from 45% to 25% at biopsy and from 33% to 9.8% at radical prostatectomy (RP) pathology. Similarly, active surveillance (AS) uptake significantly increased to 49% and 62% among nonacademic and academic sites, respectively. Decreasing rates of definitive therapies were identified: among academic sites, RP decreased from 61.1% to 25.3% and radiation therapy (RT) from 25.2% to 12%, whereas among nonacademic sites, RP decreased from 53.6% to 28% and RT from 37.8% to 21.9% (Ptrend < .001). Declines in the diagnosis and treatment of low-grade disease demonstrate an encouraging shift in PCa epidemiology. However, heterogeneity in AS utilization remains and reflects opportunities for improvement.


Assuntos
Neoplasias da Próstata , Masculino , Humanos , Neoplasias da Próstata/diagnóstico , Neoplasias da Próstata/epidemiologia , Neoplasias da Próstata/terapia , Próstata/patologia , Gradação de Tumores , Prostatectomia , Antígeno Prostático Específico
5.
Clin Genitourin Cancer ; 20(5): 423-430, 2022 10.
Artigo em Inglês | MEDLINE | ID: mdl-35701333

RESUMO

INTRODUCTION: Deferred treatment is a growing management strategy for low-risk prostate cancer. However, it is unknown whether this growth is mediated by patient factors. In this study, we sought to evaluate factors associated with deferred treatment in patients with low-risk prostate cancer and shifts in these factors after recent incorporation of active surveillance into national guidelines. MATERIALS AND METHODS: We identified 137,915 men diagnosed with low-risk prostate cancer (prostate-specific antigen <10 ng/mL, Gleason score ≤6, stage cT1-cT2a) in the National Cancer Database from 2010 to 2017. Multivariate logistic regression models were used to determine factors associated with deferred treatment. Interaction variables were added to determine whether trends in use of deferred treatment over time depend on race, income, education, and insurance status. RESULTS: The use of deferred treatment among men with low-risk prostate cancer increased from 14.7% in 2010-2011 to 46.3% in 2016-2017 (P < .001). On multivariate analysis, deferred treatment was associated with older age, more contemporary year of diagnosis, black race, lower income, higher educational attainment, government insurance, being uninsured, treatment at an academic/research facility, and treatment at a facility in New England (each P < .05). Incorporation of interaction variables showed that black race, belonging to the two lowest income quartiles, government insurance, and being uninsured became less associated with deferred treatment in recent years. CONCLUSIONS: The use of deferred treatment among men with low-risk prostate cancer increased significantly from 2010 to 2017. However, patients who were black, low-income, and not privately insured experienced smaller increases in deferred treatment. Interventions to increase uptake in these groups present opportunities to improve quality of care.


Assuntos
Antígeno Prostático Específico , Neoplasias da Próstata , Humanos , Modelos Logísticos , Masculino , Pessoas sem Cobertura de Seguro de Saúde , Gradação de Tumores , Neoplasias da Próstata/diagnóstico , Neoplasias da Próstata/terapia
6.
Curr Opin Urol ; 32(1): 85-90, 2022 01 01.
Artigo em Inglês | MEDLINE | ID: mdl-34783715

RESUMO

PURPOSE OF REVIEW: Prostate biopsy is a very commonly performed office procedure leading to the diagnosis of the most prevalent solid-organ malignancy in American men. Although the transrectal technique for prostate biopsy remains the gold standard, there is increasing interest in the transperineal approach as it offers a clean, percutaneous approach that significantly decreases the risk for infection. In this review, we discuss emerging developments in transperineal prostate biopsy that may optimize the way biopsies are performed in clinical practice. RECENT FINDINGS: Similarly, to transrectal biopsy, the transperineal approach also allows for the performance of systematic and MRI-targeted biopsy cores. As transperineal biopsy obviates the translocation of rectal bacteria to the prostate or bloodstream, in contrast to transrectal biopsy, it is feasible to forgo peri-procedural antibiotics in accordance with professional guidelines. This may attenuate antimicrobial resistance that may be associated with augmented prophylaxis. In addition, although transperineal biopsy may be traditionally performed under general anesthesia using a template grid, it may also be performed freehand under local anesthesia or sedation. Avoiding prophylactic antibiotics and general anesthesia as well as reducing infections/hospitalizations for transperineal biopsy scaled nationally will likely result in significant healthcare savings. SUMMARY: Transperineal biopsy with combined systematic and MRI-targeted cores, offers several advantages over conventional transrectal biopsy. Transperineal biopsy under local anesthesia and without periprocedural antibiotic is emerging as a promising method for prostate cancer diagnosis and surveillance.


Assuntos
Próstata , Neoplasias da Próstata , Antibacterianos/uso terapêutico , Biópsia/métodos , Humanos , Biópsia Guiada por Imagem/métodos , Masculino , Períneo/patologia , Próstata/diagnóstico por imagem , Próstata/patologia , Neoplasias da Próstata/patologia , Estudos Retrospectivos
7.
Can Urol Assoc J ; 15(10): 339-344, 2021 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-33750519

RESUMO

INTRODUCTION: We compared clinicopathological characteristics and outcomes of radical nephrectomy (RN) for small renal masses (SRM) in patients with end-stage renal disease (ESRD) before or after transplant at a high-volume urologic and transplant center. METHODS: We performed a retrospective review of patients with ESRD (glomerular filtration rate [GFR] <15 mL/min) who underwent RN for suspected malignant SRM from 2000-2018. Group 1 consisted of patients who underwent RN after transplant; group 2 underwent RN prior to transplant, and group 3 underwent RN without subsequent transplant. Dominant tumor size and histopathological characteristics, recurrence, and survival outcomes were compared between groups. Chi-squared and Mann-Whitney U tests were used to compare categorical and continuous baseline and histopathologic characteristics, respectively. Univariate analysis and log rank test were used to compare RCC recurrence rates. RESULTS: We identified 34 nephrectomies in group 1, 27 nephrectomies in group 2, and 70 nephrectomies in group 3. Median time from transplant to SRM radiological diagnosis in group 1 was 87 months, and three months from diagnosis to nephrectomy for all groups. There were no statistically significant differences between pathological dominant mass size, histological subtype breakdown, grade, or stage between the groups. Rates of benign histology were similar between the groups. Univariate analysis did not reveal a statistically significant difference in recurrence-free survival between the groups (p=0.9). CONCLUSIONS: Patients undergoing nephrectomy before or after transplant for SRM have similar indolent clinicopathological characteristics and low recurrence rates. Our results suggest that chronic immunosuppression does not adversely affect SRM biology.

8.
Urol Pract ; 8(2): 284-290, 2021 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-37145617

RESUMO

INTRODUCTION: Opioid addiction is a rising public health crisis. We evaluated if a New York State-mandated online opioid awareness course impacted our urology opioid prescription practices for outpatient endoscopic surgeries. METHODS: We completed a retrospective review of all ambulatory endoscopic cases identified by CPT codes for all adult urology faculty between February 2016 and January 2018. Patients were divided into 2 cohorts, ie pre-mandated and post-mandated training. Patient demographics, procedure details, psychiatric history and postoperative pain prescriptions were collected. Changes in opioid prescription practices prior to and after the mandated online course were reviewed. Chi-square and linear regression analyses were performed. RESULTS: A total of 356 cases were analyzed. After the training course, overall frequency of department opioid prescriptions did not change significantly (47.9% vs 47.5%, p=0.95). However, the percentage of patients receiving an oxycodone/acetaminophen prescription decreased from 90.2% to 63.0% (p <0.001) and the average number of tablets prescribed decreased (8.6 vs 16.9, p <0.001). On multivariate analysis, placement of a ureteral stent, older patient age and higher body mass index were predictors of an opioid prescription. In those patients who had a stent placed, nonopioid prescriptions increased from 42% to 88% (p <0.001). CONCLUSIONS: Overall, the New York State-mandated education session did impact opioid prescription practices for outpatient urological endoscopic surgery at our institution. The largest impact was seen within patients undergoing procedures requiring stent placement, with a decrease in total number of oxycodone/acetaminophen prescriptions and number of tablets prescribed per prescription. These data begin to demonstrate effective interventions that may impact physician practice patterns within opioid research.

9.
Urology ; 146: 101-106, 2020 12.
Artigo em Inglês | MEDLINE | ID: mdl-32777364

RESUMO

OBJECTIVE: To evaluate adherence to the American Urologic Association (AUA) best practice statement guidelines regarding antibiotic duration in the perioperative setting for endoscopic urologic surgery. We assessed concordance to these guidelines among adult urologists at a single academic institution and its correlation with postoperative positive urine cultures as it relates to the revised 2019 best practice statement. METHODS: We performed a retrospective review of all adult endoscopic ambulatory urologic surgeries performed over an 18-month period by urologists at our institution. Patient demographics, pre- and postoperative urine cultures, operative details, stent or foley use, and antibiotic prescriptions were reviewed. Chi-squared and linear regression analyses were done. RESULTS: Three hundred thirty patients were included for analysis. Sixty-two percent of patients were prescribed postoperative antibiotics, for an average of 4 days. Trimethoprim/Sulfamethoxazole and fluroquinolones were most often prescribed (43% and 38%, respectively). Intraoperative stent placement, positive urine culture within 30 days prior to surgery, and a positive urine culture within 1 year prior to surgery predicted antibiotic prescription. No significant differences were seen in rates of positive postoperative urine culture rates between cohorts that received antibiotics postoperatively vs those who did not. CONCLUSIONS: At our academic institution, we observed poor concordance with the AUA best practice statement for perioperative antibiotic prescription after ambulatory endoscopic urologic surgery. Rates of positive postoperative cultures were low and not associated with receipt or duration of antibiotic prescription at the time of surgery, supporting minimal use of antibiotics for most endoscopic cases.


Assuntos
Procedimentos Cirúrgicos Ambulatórios/efeitos adversos , Antibioticoprofilaxia/estatística & dados numéricos , Endoscopia/efeitos adversos , Complicações Pós-Operatórias/prevenção & controle , Infecções Urinárias/prevenção & controle , Procedimentos Cirúrgicos Urológicos/efeitos adversos , Centros Médicos Acadêmicos/normas , Centros Médicos Acadêmicos/estatística & dados numéricos , Idoso , Procedimentos Cirúrgicos Ambulatórios/métodos , Antibacterianos/uso terapêutico , Antibioticoprofilaxia/normas , Prescrições de Medicamentos/normas , Prescrições de Medicamentos/estatística & dados numéricos , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Complicações Pós-Operatórias/microbiologia , Guias de Prática Clínica como Assunto , Padrões de Prática Médica/normas , Padrões de Prática Médica/estatística & dados numéricos , Estudos Retrospectivos , Infecções Urinárias/microbiologia , Procedimentos Cirúrgicos Urológicos/métodos , Urologistas/normas , Urologistas/estatística & dados numéricos
10.
Curr Urol ; 13(1): 51-53, 2019 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-31579217

RESUMO

Bilateral renal cell carcinoma with tumor thrombus extension into the renal vein and/or inferior vena cava - clinical stage T3a+ - is rare. The majority of these cases arise due to a genetic predisposition. We present a case report of a 47-year-old male with bilateral, synchronous renal cell carcinoma with bilateral renal vein and inferior vena cava tumor thrombi with no identifiable familial predisposition.

11.
Urology ; 126: 1-4, 2019 04.
Artigo em Inglês | MEDLINE | ID: mdl-30605694

RESUMO

Patients with localized urethral melanoma have a high risk of recurrence and poor disease-specific survival. Multi-disciplinary approach including surgery, radiation therapy, and chemotherapy/immunotherapy is needed to maximize survival. Current research efforts include investigation of novel tyrosine kinases as well as the combination of targeted therapies with immunotherapies in this population. Combinations may provide a synergistic effect to overcome various obstacles to disease response.


Assuntos
Melanoma , Neoplasias Uretrais , Idoso , Evolução Fatal , Feminino , Humanos , Melanoma/diagnóstico , Melanoma/terapia , Neoplasias Uretrais/diagnóstico , Neoplasias Uretrais/terapia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA